|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 39/0017 | (2013.01) |
| A61K 39/095 | (2006.01) | ||
| A61K 39/102 | (2006.01) | ||
| A61K 39/0018 | (2013.01) | ||
| A61K 39/116 | (2006.01) | ||
| A61K 39/095 | (2013.01) | ||
| A61P 31/04 | (2006.01) | ||
| A61K 39/102 | (2013.01) | ||
| A61K 39/385 | (2013.01) | ||
| A61K2039/545 | (2013.01) | ||
| A61K2039/6037 | (2013.01) | ||
| A61K2039/62 | (2013.01) | ||
| A61K2039/627 | (2013.01) | ||
| A61K2039/70 | (2013.01) | ||
| A61P 11/04 | (2018.01) | ||
| A61P 11/14 | (2018.01) | ||
| A61P 31/00 | (2018.01) | ||
| A61P 31/04 | (2018.01) | ||
| A61P 31/12 | (2018.01) | ||
| A61P 31/20 | (2018.01) | ||
| A61P 37/00 | (2018.01) | ||
| A61P 37/04 | (2018.01) | ||
| A61P 43/00 | (2018.01) | ||
| C07H 3/00 | (2013.01) | ||
| C12N2730/10134 | (2013.01) | ||
| C12N2770/32634 | (2013.01) | ||
| Y02A 50/30 | (2018.01) |
| (11) | Patento numeris | 1896066 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 06762248.0 |
| Europos patento paraiškos padavimo data | 2006-06-23 | |
| (97) | Europos patento paraiškos paskelbimo data | 2008-03-12 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-10-27 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2006/006269 |
| Data | 2006-06-23 |
| (87) | Numeris | WO 2007/000342 |
| Data | 2007-01-04 |
| (30) | Numeris | Data | Šalis |
| 0513069 | 2005-06-27 | GB | |
| 0513071 | 2005-06-27 | GB | |
| 0515556 | 2005-07-28 | GB | |
| 0524204 | 2005-11-28 | GB | |
| 0526040 | 2005-12-21 | GB | |
| 0526041 | 2005-12-21 | GB |
| (72) |
BIEMANS, Ralph Leon , BE
BOUTRIAU, Dominique , BE
CAPIAU, Carine , BE
DENOEL, Philippe , BE
DUVIVIER, Pierre , BE
POOLMAN, Jan , BE
|
| (73) |
Pfizer Ireland Pharmaceuticals ,
Operations Support Group, Ringaskiddy
Cork,
IE
|
| (54) | IMMUNOGENIC COMPOSITION |
| IMMUNOGENIC COMPOSITION |